Dare Bioscience Inc (DARE)

$1.34 +0.06 (4.69%)
Market Cap 18.40M
Revenue (ttm) 1.03M
Net Income (ttm) -13.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,300.97%
Debt to Equity Ratio 0.00
Volume 133,805
Avg Vol 191,540
Day's Range N/A - N/A
Shares Out 15.08M
Stochastic %K 68%
Beta 1.03
Analysts Strong Sell
Price Target $10.25

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
DM3D
DM3D Aug. 4 at 12:50 PM
$DARE We'll that's $20,000 I'll never get back. My shares are gone; my value is gone. Slogan should be "Invest if you DARE"!
1 · Reply
NotFinancialAdvice007
NotFinancialAdvice007 Aug. 3 at 4:04 PM
$DARE shit co wow
0 · Reply
BiotechJedi1728
BiotechJedi1728 Aug. 3 at 3:08 PM
$DARE More revenue inbound. Back on this train again. Time to 5x my money again. 🤷🏻‍♂️
1 · Reply
prismmarketview
prismmarketview Jul. 28 at 6:26 PM
$DARE Daré Bioscience Partners With MyMenopauseRx to Expand DARE to PLAY Access and Build a Women's Health Ecosystem https://prismmarketview.com/dare-bioscience-partners-with-mymenopauserx-to-expand-dare-to-play-access-and-build-a-womens-health-ecosystem/
0 · Reply
darebio
darebio Jul. 28 at 2:31 PM
$DARE Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-expands-access-options-dare-playtm-and
0 · Reply
focafoca99
focafoca99 Jul. 28 at 12:45 PM
$DARE rolled out a strategic collaboration with MyMenopauseRx to broaden DARE to PLAY access for menopause care. https://www.rapidticker.com/news/dare-daré-bioscience-expands-access-options-97e031
0 · Reply
StackingWins999
StackingWins999 Jul. 24 at 5:11 PM
$DARE let’s go…
0 · Reply
jpoptions
jpoptions Jul. 22 at 3:03 PM
$DARE I am in.
0 · Reply
HMIC
HMIC Jul. 21 at 10:25 PM
$DARE Just a reminder of where this can go.
1 · Reply
puddingpop
puddingpop Jul. 21 at 7:03 PM
$DARE I hope Sabrina burns in hell for ruining this company
0 · Reply
Latest News on DARE
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

Jul 28, 2026, 8:34 AM EDT - 7 days ago

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

Jul 20, 2026, 9:01 AM EDT - 15 days ago

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

Daré Bioscience Transcript: Virtual Investor Closing Bell

Jul 14, 2026, 4:00 PM EDT - 21 days ago

Daré Bioscience Transcript: Virtual Investor Closing Bell

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Jul 9, 2026, 8:43 AM EDT - 26 days ago

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Jul 1, 2026, 8:55 AM EDT - 4 weeks ago

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Jun 25, 2026, 9:05 AM EDT - 5 weeks ago

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Jun 18, 2026, 9:20 AM EDT - 6 weeks ago

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Daré Bioscience Transcript: AGM 2026

Jun 11, 2026, 12:00 PM EDT - 7 weeks ago

Daré Bioscience Transcript: AGM 2026

Daré Bioscience Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Proxy statement: Proxy filing

Dare Bioscience receives NIH funding award notice to advance DARE-HPV

2026-05-26T12:19:36.000Z - 2 months ago

Dare Bioscience receives NIH funding award notice to advance DARE-HPV

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

May 26, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare Bioscience initiates DARE-HPV clinical study

2026-05-18T12:14:40.000Z - 2 months ago

Dare Bioscience initiates DARE-HPV clinical study

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

May 18, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

Daré Bioscience Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 2 months ago

Daré Bioscience Earnings Call Transcript: Q1 2026

Daré Bioscience Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 2 months ago

Daré Bioscience Quarterly report: Q1 2026

Daré Bioscience Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 2 months ago

Daré Bioscience Earnings release: Q1 2026

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:01 PM EDT - 2 months ago

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

2026-05-12T19:41:03.000Z - 3 months ago

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

May 12, 2026, 8:00 AM EDT - 3 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Daré Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 4 months ago

Daré Bioscience Earnings Call Transcript: Q4 2025

Daré Bioscience Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 4 months ago

Daré Bioscience Annual report: Q4 2025

Daré Bioscience Earnings release: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 4 months ago

Daré Bioscience Earnings release: Q4 2025

Daré Bioscience Slides: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 4 months ago

Daré Bioscience Slides: Q4 2025

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 4:01 PM EDT - 4 months ago

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

On National Viagra Day, Women Finally Claim Their Turn:

Mar 23, 2026, 8:00 AM EDT - 4 months ago

On National Viagra Day, Women Finally Claim Their Turn:

Dare Bioscience receives NIH funding award notice for DARE-PTB1

2026-03-16T12:39:51.000Z - 5 months ago

Dare Bioscience receives NIH funding award notice for DARE-PTB1

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Daré Bioscience Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:40 PM EST - 5 months ago

Daré Bioscience Transcript: TD Cowen 46th Annual Health Care Conference

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

2026-02-23T13:22:55.000Z - 5 months ago

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Feb 23, 2026, 8:00 AM EST - 5 months ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare announces availability of telehealth consultations for DARE to PLAY

2026-02-11T13:23:08.000Z - 6 months ago

Dare announces availability of telehealth consultations for DARE to PLAY

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

2025-12-10T13:10:49.000Z - 8 months ago

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dec 10, 2025, 8:00 AM EST - 8 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dare Bioscience announces return of rights to Oveprene

2025-12-01T13:20:39.000Z - 8 months ago

Dare Bioscience announces return of rights to Oveprene

Dare Bioscience receives $3.6M in additional grant funding

2025-11-24T13:30:31.000Z - 9 months ago

Dare Bioscience receives $3.6M in additional grant funding

Daré Bioscience Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Daré Bioscience Earnings Call Transcript: Q3 2025

Daré Bioscience Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Daré Bioscience Quarterly report: Q3 2025

Daré Bioscience Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Daré Bioscience Earnings release: Q3 2025

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 9 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Dare Bioscience to host webinar on the DARE to PLAY

2025-11-11T13:10:31.000Z - 9 months ago

Dare Bioscience to host webinar on the DARE to PLAY

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Dare Bioscience to receive up to $300,000 to conduct landscape review

2025-11-03T13:20:56.000Z - 9 months ago

Dare Bioscience to receive up to $300,000 to conduct landscape review

Dare Bioscience receives $4M non-dilutive grant installment

2025-10-06T12:20:36.000Z - 10 months ago

Dare Bioscience receives $4M non-dilutive grant installment

Dare Bioscience to receive up to $499,000 to support preeclampsia research

2025-09-24T12:11:38.000Z - 11 months ago

Dare Bioscience to receive up to $499,000 to support preeclampsia research

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 11 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Dare Bioscience upgraded to Buy from Hold at Maxim

2025-09-04T11:45:08.000Z - 11 months ago

Dare Bioscience upgraded to Buy from Hold at Maxim

Daré Bioscience Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q2 2025

Daré Bioscience Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Quarterly report: Q2 2025

Daré Bioscience Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q2 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

2025-07-29T12:21:48.000Z - 1 year ago

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 1 year ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Dare Bioscience to host webinar on Sildenafil cream

2025-07-21T12:27:31.000Z - 1 year ago

Dare Bioscience to host webinar on Sildenafil cream

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

2025-07-15T00:37:00.000Z - 1 year ago

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 1 year ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Proxy statement: Proxy Filing

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Slides: Corporate Presentation

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Daré Bioscience Slides: Corporate Presentation

Daré Bioscience Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q1 2025

Daré Bioscience Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Quarterly report: Q1 2025

Daré Bioscience Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q1 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Apr 9, 2025, 4:00 PM EDT - 1 year ago

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Daré Bioscience Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q4 2024

Daré Bioscience Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q4 2024

Daré Bioscience Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Annual report: Q4 2024

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience Registration statement: Registration Filing

Nov 15, 2024, 7:00 AM EST - 1 year ago

Daré Bioscience Registration statement: Registration Filing

Daré Bioscience Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings Call Transcript: Q3 2024

Daré Bioscience Earnings release: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings release: Q3 2024

Daré Bioscience Quarterly report: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Quarterly report: Q3 2024

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q2 2024

Daré Bioscience Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q2 2024

Daré Bioscience Earnings release: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q2 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 2 years ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q1 2024

Daré Bioscience Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q1 2024

Daré Bioscience Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q1 2024

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience Registration statement: Registration Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Registration statement: Registration Filing

Daré Bioscience Registration statement: Registration Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Registration statement: Registration Filing

Daré Bioscience Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q4 2023

Daré Bioscience Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Annual report: Q4 2023

Daré Bioscience Earnings release: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q4 2023

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

DM3D
DM3D Aug. 4 at 12:50 PM
$DARE We'll that's $20,000 I'll never get back. My shares are gone; my value is gone. Slogan should be "Invest if you DARE"!
1 · Reply
NotFinancialAdvice007
NotFinancialAdvice007 Aug. 3 at 4:04 PM
$DARE shit co wow
0 · Reply
BiotechJedi1728
BiotechJedi1728 Aug. 3 at 3:08 PM
$DARE More revenue inbound. Back on this train again. Time to 5x my money again. 🤷🏻‍♂️
1 · Reply
prismmarketview
prismmarketview Jul. 28 at 6:26 PM
$DARE Daré Bioscience Partners With MyMenopauseRx to Expand DARE to PLAY Access and Build a Women's Health Ecosystem https://prismmarketview.com/dare-bioscience-partners-with-mymenopauserx-to-expand-dare-to-play-access-and-build-a-womens-health-ecosystem/
0 · Reply
darebio
darebio Jul. 28 at 2:31 PM
$DARE Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-expands-access-options-dare-playtm-and
0 · Reply
focafoca99
focafoca99 Jul. 28 at 12:45 PM
$DARE rolled out a strategic collaboration with MyMenopauseRx to broaden DARE to PLAY access for menopause care. https://www.rapidticker.com/news/dare-daré-bioscience-expands-access-options-97e031
0 · Reply
StackingWins999
StackingWins999 Jul. 24 at 5:11 PM
$DARE let’s go…
0 · Reply
jpoptions
jpoptions Jul. 22 at 3:03 PM
$DARE I am in.
0 · Reply
HMIC
HMIC Jul. 21 at 10:25 PM
$DARE Just a reminder of where this can go.
1 · Reply
puddingpop
puddingpop Jul. 21 at 7:03 PM
$DARE I hope Sabrina burns in hell for ruining this company
0 · Reply
Teddy313
Teddy313 Jul. 21 at 5:15 PM
$DARE This is really a shame I own this for over 10 years and I still am buried in it. SM on 2 conference calls said "This is the year for investors" I can't believe I believed her....Well we have 5 months left, anyone believe in medicals?
2 · Reply
Hudafin
Hudafin Jul. 21 at 4:30 AM
$DARE when is the next reverse split? This shit is garbage.
2 · Reply
TheDonQuixote1492
TheDonQuixote1492 Jul. 21 at 12:30 AM
$DARE why call it a “Virtual Bus Tour” These broads are just on vacations with our money doing seminars then act as if calling it something cool to speak to shareholders is somehow hip and okay. DEI at its peak.
0 · Reply
HMIC
HMIC Jul. 20 at 8:04 PM
$DARE Buy order for 1000 shares at 1.34 will not print.
0 · Reply
Don_Frye
Don_Frye Jul. 20 at 7:00 PM
$DARE a sell rating from Weiss on 7-17 = the cause of this drop imo
0 · Reply
ElysiumAnalytics
ElysiumAnalytics Jul. 20 at 6:59 PM
$DARE Sabrina and friends should be held accountable for running this company with so much potential directly into the ground….
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Jul. 20 at 6:26 PM
$DARE 👇
0 · Reply
HMIC
HMIC Jul. 20 at 6:08 PM
$DARE Got some cheap shares today , sold some not so cheap shares recently. Life is good
0 · Reply
focafoca99
focafoca99 Jul. 20 at 5:25 PM
$DARE initiated a virtual bus tour webinar series to showcase its commercial strategy and growth opportunities. https://www.rapidticker.com/news/dare-daré-bioscience-launches-nationwide-virtual-706c2f
0 · Reply
prismmarketview
prismmarketview Jul. 20 at 4:06 PM
PRISM Mid-Day Movers: Crypto Mining and Emerging MedTech are Today’s leaders. Soluna Holdings’ (NASDAQ: $SLNH ) is enjoying a strong bounce today, with shares up roughly 23% and pushing further into the low‑$1 range. Neuronetics, Inc. (NASDAQ: $STIM ) is rallying today, with the stock up about 18% to 1.915 from a prior close of 1.62. Other Notable Movers: Archer Aviation ( $ACHR ) up 16% Sky Quarry ( $SKYQ ) up 13% Daré Bioscience ( $DARE ) down -27% https://prismmarketview.com/prism-mid-day-movers-crypto-mining-and-emerging-medtech-are-todays-leaders/
0 · Reply
cshin80
cshin80 Jul. 20 at 3:33 PM
$DARE what happened
1 · Reply
Don_Frye
Don_Frye Jul. 20 at 2:48 PM
$DARE pos
0 · Reply